In this presentation from the “MPN Therapies: Emerging Concepts for Enhanced Outcomes” symposium, Dr. Paola Guglielmelli discusses the clinical benefit of JAK2 inhibitors in patients with myeloproliferative neoplasms.
A continuing education program related to this video is offered at the following location:
http://elc.imedex.com/ELC/Activity-Search.aspx?search=7212
© 2016 Imedex, LLC.
Advertisement Single Between Content
Advertisement Single Between Content
Advertisement Single Between Content
Advertisement Single Below Content
Advertisement Single Below Content
Advertisement Single Below Content